Released Nov 5, 2025, before the open
10-Q filed Nov 5, 2025, 36 days after period end · 0001628280-25-049238
Q3 2025 · 10-Q
Revenue$8.15M$8.15M +4.4% vs Q3 2024+7.9% vs Q2 2025
Net Income-$15.85M-$15.85M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.25-$0.25 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$18,501,000N/M
Operating Cash Flowderived-$18,860,000N/M
Free Cash Flowderived-$18,860,000N/M
Margins · derived
Operating margin-226.9%+78.6 pt vs Q3 2024
Net margin-194.4%+50.5 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $8.15M | $7.81M | $17.48M | $6.63M |
| Net Income | -$15.85M | -$19.12M | -$14.35M | -$25.77M |
| EPS Diluted | -$0.25 | -$0.31 | -$0.34 | -$0.62 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR